PDB2 - Rate of Hypoglycemic Events in Patients Using Basal Insulin Analogues: A Real World Analysis of four Grade III Class A Hospitals in China

Abstract

To analyze the rate of hypoglycemic events in patients using basal insulin analogues in China. Retrospective electronic health record data from 4 Grade III Class A hospitals in China from January 2012 to May 2017 was used. Including criteria were patients of type 1 and type 2 diabetes treated with basal insulin analogues, including Hypoglycemia was identified with glycemic value (≤3.9 mmol/L; <2.8 mmol/L and requiring assistance of another person for severe hypoglycemia) supplemented with Chinese descriptions. 4,812 patients were identified with mean age of 60.8 years, 49.1% being male, mean fasting blood glucose of 9.34 mmol/L. 2,393, 991 and 1,428 patients were treated with IGlar, IDet and rIGlar, respectively. Overall, 912(19.0%) patients experienced hypoglycemia including 451(18.8%) patients treated with IGlar, 104(10.5%) patients treated with IDet and 357(25.0%) patients treated with rIGlar. The overall rate of all hypoglycemia was 109.4 events/100 patient-year. The rate of all hypoglycemia among patients treated with IGlar, IDet and rIGlar were 117.06, 82.97, and 114.06 respectively. The overall rate of severe hypoglycemia was 12.84 events/100 patient-year. The rate of severe hypoglycemia among patients treated with IGlar, IDet and rIGlar were 4.39, 0.84 and 46.23 respectively. The overall rate of non-severe hypoglycemia was 96.56 events/100 patient-year. The rate of non-severe hypoglycemia among patients treated with IGlar, IDet and rIGlar were 112.66, 82.13 and 67.84 respectively. The rates of all hypoglycemia and severe hypoglycemia were significantly less with IDet than IGlar and rIGlar (all P<0.05), based on comparison between IDet and IGlar, and comparison between IDet and rIGlar. Hypoglycemic events in patients treated with basal insulin analogues in China was common. There were differences in rate of hypoglycemic events depending on the basal insulin analogue used, with lowest hypoglycemic risk with IDet.